Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial
T. Greulich (Marburg, Germany), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), N. Lossi (Nuernberg, Germany), M. Aalamian-Mattheis (Basel, Switzerland), X. Nunez (Barcelona, Spain), V. Pagano (Barcelona, Spain), F. Patalano (Basel, Switzerland), A. Clemens (Basel, Switzerland), K. Kostikas (Basel, Switzerland)
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Session: Clinical determinants and biomarkers of COPD
Session type: Poster Discussion
Number: 2014
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Greulich (Marburg, Germany), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), N. Lossi (Nuernberg, Germany), M. Aalamian-Mattheis (Basel, Switzerland), X. Nunez (Barcelona, Spain), V. Pagano (Barcelona, Spain), F. Patalano (Basel, Switzerland), A. Clemens (Basel, Switzerland), K. Kostikas (Basel, Switzerland). Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial. 2014
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: